© 2025 Orbital Therapeutics • Privacy Policy • Terms of Use
Dr. Raff to lead Clinical and Regulatory Operations to guide advancement of OTX-201, a potential best-in-class program for B cell-driven autoimmune diseases, toward clinical development in 1H’26
CAMBRIDGE, Mass. – September 4, 2025 – Orbital Therapeutics, a biotechnology company pioneering a new generation of RNA medicines that reprogram the immune system in vivo to treat disease at its source, today announced the appointment of Adam Raff, M.D., Ph.D., as Senior Vice President, Clinical Development. Dr. Raff will oversee Orbital’s clinical and regulatory strategy and execution and will serve as a key member of the company’s executive leadership team.
“Adam brings exceptional depth of experience in translating innovative science into impactful therapeutics, with a proven track record of successfully leading clinical development programs from discovery through pivotal trials,” said Ron Philip, Chief Executive Officer at Orbital. “His expertise in immunology and inflammatory diseases, combined with his unique background as a practicing physician-scientist and drug developer, makes him ideally suited to advance Orbital’s diverse RNA medicine portfolio. Adam joins at just the right time, as we progress OTX-201 through IND-enabling studies following encouraging preclinical data, with clinical development expected to begin in the first half of 2026.”
“Orbital’s mission to develop a new generation of in vivo RNA medicines represents an extraordinary opportunity to transform how we treat human disease,” said Dr. Raff. “The company’s first-in-kind platform at the intersection of RNA technology, delivery methods, and AI-guided design has tremendous potential to address unmet medical needs across multiple therapeutic areas. I’m excited to join this talented team and help translate Orbital’s innovative science into life-changing therapies for patients.”
Dr. Raff brings over a decade of experience in drug development and clinical research, spanning early discovery through late-stage clinical development, with extensive expertise in immunology and inflammatory disorders. Most recently, he served as Vice President and Head of Clinical Development at Montai Therapeutics, where he advanced multiple programs including the lead asset from discovery to IND-enabling studies. He previously held progressive leadership roles at EQRx (acquired by Revolution Medicines in 2023) as Vice President of Immunology and Senior Medical Director, and at LEO Pharma as Director of Translational Medicine. Dr. Raff earned his M.D. and Ph.D. in Systems Biology with an immunology focus from the University of Southern California and completed his dermatology residency through the Harvard Combined Dermatology Residency Program.
About Orbital Therapeutics
Orbital Therapeutics is advancing a new generation of RNA medicines designed to reprogram cells in vivo, treating diseases at their source. This approach offers patients a simpler, safer, and more accessible alternative to today’s complex treatments. Built from day one with a fully integrated platform spanning circular and linear RNA, targeted delivery, and AI-guided design, Orbital is working to develop durable, programmable therapies tailored to the distinct biology of each disease. The company’s lead program, OTX-201, targets autoimmune disease through B cell depletion to reset the immune system. Orbital’s platform is built for expansion into broader autoimmune indications, oncology, next-generation vaccines, and protein therapeutics. Led by a team with deep expertise in RNA science, clinical development, and commercialization, Orbital is united by a shared commitment to reach more patients, in more places, with fewer barriers. Learn more at www.orbitaltx.com.
Investor Contact
Alex Straus, THRUST
alex@thrustsc.com
Media Contact
Josie Butler, 1AB
josie@1abmedia.com
CAMBRIDGE, Mass. – March 6, 2025 – Orbital Therapeutics, a company dedicated to enhancing global health by unleashing the full potential of RNA medicines, today announced the appointment of Geno Germano to its Board of Directors. Mr. Germano is a 35-year biopharma and life sciences industry veteran with extensive development and commercialization senior leadership experience across multiple therapeutic areas.
“We are excited to welcome Geno to Orbital and will benefit from his deep expertise in portfolio strategy, drug development, and commercialization,” said Ron Philip, chief executive officer of Orbital. “Among his many accomplishments, Geno has a strong track record in our core areas of focus, including immunology and oncology, and his insights will be invaluable as we advance our pipeline toward multiple development candidates and ultimately to treating patients in need.”
“I am thrilled to join Orbital’s Board and help the company realize the full potential of RNA medicines,” said Mr. Germano. “Orbital’s cutting-edge RNA technologies have the potential to revolutionize treatment across multiple disease areas. I am eager to contribute to the company’s next phase of growth and help make a meaningful change with important new medicines.”
Geno Germano most recently served as president and chief executive officer of Elucida Oncology, a clinical-stage biotechnology company focused on the development of novel nanoparticle drug conjugates. Prior to Elucida, he was president of Intrexon (now known as Precigen), a leader in the application of synthetic biology across multiple market segments. Earlier in his career, Mr. Germano held executive leadership roles at leading biopharmaceutical companies. As group president of Pfizer’s global innovative pharmaceutical business, he managed a $20 billion global portfolio and led the late-stage development of more than a dozen drug candidates across five therapeutic areas. He also served as president of Wyeth U.S., overseeing its pharmaceutical and women’s healthcare businesses, and as executive vice president of its vaccines division. Additionally, he held senior roles at Johnson & Johnson.
Mr. Germano previously served on the boards of several biopharma industry organizations and public companies, including the Biotechnology Innovation Organization, the Healthcare Businesswomen’s Association, Zoetis, Bioverativ, and The Medicines Company. He currently serves as a board director at Sage Therapeutics and Precision Biosciences. Mr. Germano obtained his B.S. degree at the Albany College of Pharmacy and Health Sciences.
About Orbital Therapeutics
Orbital Therapeutics aims to enhance global health by unleashing the full potential of RNA-based medicines to treat human disease in ways that were not previously possible. The company is leveraging its first-in-kind platform at the intersection of RNA technology, delivery methods, data science, and automation to develop an expansive portfolio of medicines, initially focused in the areas of immunomodulation for autoimmune disease and oncology, next-generation vaccines, and protein therapeutics. Founded by experts in the fields of genetic medicine and RNA development and delivery, Orbital has an operational structure designed to harness the ingenuity of a deep and diverse team of scientists, drug developers, and business leaders. For more information, please visit www.OrbitalTx.com.
Investor Contact
Monique Allaire, THRUST
monique@thrustsc.com
Media Contact
Dan Budwick, 1AB
dan@1abmedia.com
This links to an external website.